Based on our previous finding that HBV promotes liver cancer cell survival by upregulation of cIAP2 expression via PI3K/Akt/NF-κB signaling pathway, we, in the current study, further investigated whether HBV-induced cIAP2 expression was involved in sorafenib resistance in liver cancer. The gene discussed is AKT1; the disease is liver cancer.